1. Home
  2. ADMA vs URGN Comparison

ADMA vs URGN Comparison

Compare ADMA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

N/A

Current Price

$13.26

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$29.14

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ADMA
URGN
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2012
2016

Fundamental Metrics

Financial Performance
Metric
ADMA
URGN
Price
$13.26
$29.14
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$18.00
★ $60.71
AVG Volume (30 Days)
★ 3.8M
1.4M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.57
N/A
Revenue
★ $42,219,783.00
$1,128,000.00
Revenue This Year
$4.49
$191.08
Revenue Next Year
$14.91
$67.34
P/E Ratio
$23.39
★ N/A
Revenue Growth
★ 43.85
N/A
52 Week Low
$7.21
$16.50
52 Week High
$20.46
$50.81

Technical Indicators

Market Signals
Indicator
ADMA
URGN
Relative Strength Index (RSI) 61.74 43.46
Support Level $7.84 $24.34
Resistance Level $13.77 $31.53
Average True Range (ATR) 0.74 2.76
MACD 0.02 0.66
Stochastic Oscillator 74.43 50.76

Price Performance

Historical Comparison
ADMA
URGN

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: